Tenax Therapeutics, Inc. (TENX) fair value analysis
Nasdaq · Updated 2026-10-19
TENX price how computed
Valuation status
No fair-value estimate yetTENX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for TENX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $1.36
- Sector
- Healthcare
- 12-month range
- $1.36–$18.32
- Market cap
- $50.9M
- From 52-week high
- -92.6%
- Shares outstanding
- 37.4M
- Rank in Healthcare by quality score
- #298 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Tenax Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases. The company operates in the United States and is listed on the Nasdaq exchange.
TENX currently ranks #298 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $50.9M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-1.48
- Shares outstanding
- 37.4M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 22 · oversold
- 50-day average
- $2.08
- 200-day average
- $10.66
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+7.9%)
2026-03 ▲ beat (+12.5%)
2025-12 ▲ beat (+8.4%)
2025-09 ▲ beat (+64.3%)
2025-06 ▲ beat (+40.0%)
2025-03 ▲ beat (+31.7%)
2024-12 ▲ beat (+57.6%)
2024-09 ▲ beat (+86.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 4 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $12.6
- Target vs last price
- +826.5%
What our data shows for TENX
- Shares are trading in the lower third of their 12-month price range of $1.36–$18.32.
- The 14-day relative strength index sits at an oversold 22.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TENX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the TENX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TENX, a healthcare sector stock, has shifted into oversold territory according to its Relative Strength Index this week, moving from a neutral zone reading. The stock's valuation assessment remains pending a complete analysis at this time.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TENX stock undervalued?
TickrTrends has no fair-value estimate for TENX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is TENX's TickrTrends verdict?
TENX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does TENX compare to other Healthcare stocks?
TENX ranks #298 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TENX overbought or oversold?
TENX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does TENX report earnings next?
TENX's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does TENX usually beat earnings estimates?
Over its last 8 reported quarters TENX beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TENX?
Of 10 analysts covering TENX, 6 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $12.6 (+826.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
TENX vs CMPS · TENX vs MENS · TENX vs NVCT · TENX vs SANA · TENX vs VALN